Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects
- 4 February 2003
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (3) , 361-367
- https://doi.org/10.1046/j.1365-2036.2003.01455.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Safety Profile of LansoprazoleDrug Safety, 1999
- The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non‐encapsulated granulesAlimentary Pharmacology & Therapeutics, 1998
- The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pHJournal of Clinical Gastroenterology, 1997
- Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tubeClinical Therapeutics, 1996
- Evaluation of the Effect of Lansoprazole in Suppressing Acid Secretion Using 24-Hour Intragastric pH MonitoringJournal of Clinical Gastroenterology, 1995
- Lansoprazole: an alternative method of administration of a capsule dosage formulationClinical Therapeutics, 1995
- Comparison of lansoprazole with omeprazole on 24‐hour pH, acid secretion and serum gastrin in healthy volunteersAlimentary Pharmacology & Therapeutics, 1994
- Age‐related differences in the pharmacokinetics and pharmacodynamics of lansoprazoleBritish Journal of Clinical Pharmacology, 1993
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Pharmacokinetics and Metabolism of Omeprazole in ManScandinavian Journal of Gastroenterology, 1986